Treatment of HIV infection with the CCR5 antagonist maraviroc

被引：25
|
作者：
Kromdijk, Wiete [1 ]
Huitema, Alwin D. R. [1 ]
Mulder, Jan Willem [2 ]
机构：
[1] Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Slotervaart Hosp, Dept Internal Med, NL-1066 EC Amsterdam, Netherlands
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 07期
关键词：
TREATMENT-EXPERIENCED PATIENTS; CYP3A4; INHIBITORS; CLINICAL-TRIALS; PHARMACOKINETICS; CORECEPTOR; RESISTANCE; SAFETY; AIDS; TOLERABILITY; PROGRESSION;
D O I：
10.1517/14656561003801081
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered in this review: For this review, data from pharmacokinetic, Phase II and III clinical trials were reviewed. What the reader will gain: The objectives of this review were to discuss the pharmacokinetics and clinical efficacy and safety of maraviroc in treatment-experienced and -naive HIV patients with R5-tropic virus. Additionally, tropism testing was discussed. Take home message: Maraviroc is effective in previously treated patients with R5-tropic virus only. Also, maraviroc will be an attractive option for HIV-1-infected treatment-naive patients with R5-tropic viruses only, once genotypic assays have been validated.
引用
收藏
页码：1215 / 1223
页数：9
相关论文
共 50 条
  • [1] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
    Van Der Ryst, Elna
    [J]. FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [2] Maraviroc - The first CCR5 antagonist for the treatment of HIV
    Girotto, Jennifer E.
    [J]. FORMULARY, 2007, 42 (10) : 601 - 608
  • [3] Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection
    Yost, Raymond
    Pasquale, Timothy R.
    Sahloff, Eric G.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (08) : 715 - 726
  • [4] Drug evaluation: Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS
    Meanwell, Nicholas A.
    Kadow, John F.
    [J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (08) : 669 - 681
  • [5] Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc
    Latinovic, Olga
    Kuruppu, Janaki
    Davis, Charles
    Le, Nhut
    Heredia, Alonso
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 1497 - 1510
  • [6] Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
    Kravchenko, A. V.
    [J]. TERAPEVTICHESKII ARKHIV, 2013, 85 (11): : 125 - +
  • [7] Overcoming hERG affinity in the discovery of maraviroc; A CCR5 antagonist for the treatment of HIV
    Price, David A.
    Armour, Duncan
    de Groot, Marcel
    Leishman, Derek
    Napier, Carolyn
    Perros, Manos
    Stammen, Blanda L.
    Wood, Anthony
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1140 - 1151
  • [8] Maraviroc: a new CCR5 antagonist
    Sayana, Shilpa
    Khanlou, Homayoon
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) : 9 - 19
  • [9] Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
    Lorenzen, Thore
    [J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 151 - 156
  • [10] Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
    van der Ryst, Elna
    Heera, Jayvant
    Demarest, James
    Knirsch, Charles
    [J]. COMPANION DIAGNOSTICS: FROM BIOMARKER IDENTIFICATION TO MARKET ENTRY, 2015, 1346 : 7 - 17
12345